Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,

Published byDeirdre Mason Modified over 6 years ago

Similar presentations

Presentation on theme: "Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,"— Presentation transcript:

1 Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel, PhD, Robert L. Kormos, MD, Lynne W. Stevenson, MD, Francis D. Pagani, MD, PhD, Marissa A. Miller, DVM, MPH, J.T. Baldwin, PhD, James B. Young, MD  The Journal of Heart and Lung Transplantation  Volume 32, Issue 2, Pages (February 2013) DOI: /j.healun Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

2 Figure 1 Time of cumulative hospital participation and patients entered into the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database. Between June 23, 2006 and June 30, 2012, 145 hospitals participated in INTERMACS, and 131 of these hospitals actively contributed information on 6,633 patients. Cumulative patient accrual and the number of participating hospitals over this time period are displayed. BTT, bridge to transplant; DT, destination therapy. HMII, HeartMate II. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

3 Figure 2 Categories of patients who received durable mechanical circulatory support devices in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database between June 2006, and June 2012 are shown. LVAD, left ventricular assist device; RVAD, right ventricular assist device; TAH, total artificial heart. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

4 Figure 3 Primary adult implants in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database are shown by year of implant. LVAD, left ventricular assist device; TAH, total artificial heart. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

5 Figure 4 Primary adult implants as destination therapy are shown by year of implant. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

6 Figure 5 Primary adult left ventricular assist devices (LVADs) and biventricular assist devices BIVADs) are shown stratified by continuous-flow vs pulsatile pumps. Patients were censored at time of transplant or device explant. The error bars indicate±1 standard error. BTT, bridge to transplant; DT, destination therapy. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

7 Figure 6 Actuarial and parametric survival is shown after implantation of primary continuous-flow left ventricular assist devices (LVAD) and biventricular assist devices (BIVAD). The lower curve indicates the hazard function, or instantaneous risk, over time. The dashed lines indicate the 70% confidence limits. BTT, bridge to transplant; DT, destination therapy. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

8 Figure 7 Actuarial survival is shown stratified by age at implant. The error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

9 Figure 8 Actuarial survival is shown stratified by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profile Level. The error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

10 Figure 9 Nomogram depicts a solution of the multivariate risk factor equation, showing the interaction between age and Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Levels. The average risk profile for each of the INTERMACS levels is illustrated. The dashed lines indicate the 70% confidence limits. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

11 Figure 10 Actuarial survival is depicted stratified by implant strategy of destination therapy (DT), bridge to transplant (BTT), or bridge to candidacy (BTC). The error bars indicate±1 standard error. BIVAD, biventricular assist device; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

12 Figure 11 Nomogram depicts solution of the risk factor equations for destination therapy (DT) and bridge-to-transplant (BTT) plotted against age at implant. Dashed lines indicate the 70% confidence limits. BIVAD, biventricular assist device; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

13 Figure 12 Actuarial survival after device implant, stratified by severity of renal dysfunction. Error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; BUN, blood urea nitrogen; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

14 Figure 13 Actuarial survival after device implant, stratified by severity of right ventricular dysfunction. Error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device; RAP, right atrial pressure; RHF, right heart failure. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

15 Figure 14 Nomogram depicts the solution of the risk factor equation for surgical complexities. Dashed lines indicate the 70% confidence limits. Hx Card Surg, history of cardiac surgery; Both, prior cardiac surgery and concomitant procedure(s) at time of implant. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. Depiction is as in Figure 11. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

16 Figure 15 Actuarial freedom from stroke. The error bars indicate±1 standard error. LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

17 Figure 16 Actuarial freedom from device exchange or death related to device malfunction, stratified by device type. MCSD, mechanical circulatory support device. The error bars indicate±1 standard error. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

18 Figure 17 Actuarial freedom from pump-related infections (PRI). Note: a patient can have multiple locations for a single infection episode, therefore the total number of infection locations will not add up to the total number of patients. The error bars indicate±1 standard error. LVAD, left ventricular assist device; RVAD, right ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

19 Figure 18 Actuarial freedom from pump-related infections (PRI), stratified by Interagency Registry for Mechanically Assisted Circulatory Support (NTERMACS) profile level. Error bars indicate±1 standard error. LVAD, left ventricular assist device; NYHA, New York Heart Association; RVAD, right ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

20 Figure 19 Actuarial freedom from any of the following adverse events: infection, bleeding, device malfunction, stroke, or death. Error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

21 Figure 20 Freedom from adverse events listed in Figure 19, stratified by left (LVAD) or biventricular (BIVAD) support. Error bars indicate±1 standard error. BTT, bridge to transplant; DT, destination therapy. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

22 Figure 21 Freedom from adverse events listed in Figure 19, stratified by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) level. Error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

23 Figure 22 Freedom from adverse events listed in Figure 19, stratified by age. Error bars indicate±1 standard error. BIVAD, biventricular assist device; BTT, bridge to transplant; DT, destination therapy; LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

24 Figure 23 Visual analog scale (VAS) of general well-being before and after device implant. The numbers in parenthesis indicate number of responses received by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). CF LVAD, continuous-flow left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

25 Figure 24 Self-care component of the study before and after device implant. CF LVAD, continuous-flow left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

26 Figure 25 Usual activities component of study before and after device implant. CF LVAD, continuous flow left ventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

Download ppt "Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,"

Similar presentations

Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate.

Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate.
Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.

Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,

Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.

Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.

MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.
INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.

INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.
Session III: Linking Intermacs to the World: The Power of Collaboration Intermacs and the ISHLT Registry for Mechanically Assisted Circulatory Support.

Session III: Linking Intermacs to the World: The Power of Collaboration Intermacs and the ISHLT Registry for Mechanically Assisted Circulatory Support.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,
Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,

Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
Tomislav Mihaljevic, MD, Edward R

Tomislav Mihaljevic, MD, Edward R
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
INTERMACS 10th Annual Meeting March , 2016 Quality of Life

INTERMACS 10th Annual Meeting March , 2016 Quality of Life
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
Jennifer A. Cowger, MD, Matthew A

Jennifer A. Cowger, MD, Matthew A

Similar presentations

Ads by Google